Last edition
News about "Vishnukant Bhutada"
Shilpa Biologicals Commissions ADC Drug Substance GMP Facility in India
Shilpa Biologicals has launched an integrated Antibody Drug Conjugate (ADC) drug substance GMP facility in India, expanding Shilpa Medicare’s 25+ years of expertise in highly potent compound manufacturing.
Vishnukant Bhutada | 26/06/2026 | By News Bureau
Shilpa Medicare Targets US Approval for Oeris After Successful Phase Three Trial
Shilpa Medicare seeks licensing partners for extended-release ondansetron injection to treat chemotherapy-induced nausea and vomiting.
Vishnukant Bhutada | 09/01/2026 | By News Bureau | 208
Koanna International and PPI to Form JV to Build New Pharma Manufacturing Facility in Saudi Arabia
Pharma Pharmaceutical Industries & Biological Products (PPI) of Saudi Arabia and Koanna International FZ LLC, a wholly-owned subsidiary of Shilpa Medicare, have signed a definitive agreement to establish a joint venture to set up a pharma manufacturing facility in Saudi Arabia.
Vishnukant Bhutada | 28/08/2025 | By Mrinmoy Dey | 617
Alveolus Bio Secures Strategic Investment from Shilpa Medicare
Alveolus Bio has announced a strategic financing round led by Shilpa Medicare, which will also serve as its exclusive global development and manufacturing partner to accelerate clinical advancement of its inhaled biotherapeutics for respiratory diseases.
Vishnukant Bhutada | 04/08/2025 | By Mrinmoy Dey | 211
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy